Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05298475
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT05298475
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05298475. Non-randomized; no masking; primary purpose treatment. Start 2022-04-01 (anticipated); primary completion 2023-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Statin
- Intervention (Drug)
- PCSK9 inhibitor
- Intervention (Drug)
- PCSK9 inhibitor
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
Record details
- Record id
cardio:ct-nct05298475- Content hash
0789f43bfa63ce556a7a583bdbb5b6ac85092bb12c6f41dce30db93bc2457bb8